Short answer
UroGen Pharma Ltd. (URGN) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $27M (up 9.0% year over year) with net income of −$33M.
Q3 2025 key financials · XBRL
- Revenue
- $27M
- +9.0% YoY · +13.5% QoQ
- Net income
- −$33M
- −40.9% YoY · +33.2% QoQ
- Operating margin
- -99.7%
- Gross margin
- 88.1%
- EPS (diluted)
- −$0.69
- −40.8% YoY · +34.3% QoQ
Source: XBRL data from the UroGen Pharma Ltd. (URGN) Q3 2025 10-Q on SEC EDGAR. USD.
UroGen Pharma Ltd. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Zusduri strongest product milestone, FDA approval June 12, 2025
- UGN-103 UTOPIA enrollment completed with 99 patients and 77.8% three-month CR rate
- UGN-301 development discontinued in November 2025; no significant additional costs expected
Risk Factors
- New commercialization exposure: Zusduri launch began in late June 2025, increasing dependence on successful adoption of two products
- Financial condition: accumulated deficit reached $933.4 million as of September 30, 2025
- Capital access: approximately $19.1 million remained available under the $100.0 million ATM facility
- Debt risk: elected not to draw the $75.0 million fourth Pharmakon tranche by August 29, 2025
- Compliance risk: Pharmakon covenants restrict additional debt, asset sales, liens, and equity distributions
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UroGen Pharma Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.